Loading clinical trials...
Loading clinical trials...
A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients With Advanced Solid Tumours That Have Progressed Following Therapy With Current Standard of Care
Conditions
Interventions
RXC004
RXC004
+3 more
Locations
13
Australia
Wollongong Hospital
Wollongong, New South Wales, Australia
The Alfred Hospital - Alfred Health
Melbourne, Victoria, Australia
Cambridge University Hospital NHS Foundation Trust
Cambridge, United Kingdom
Beatson West of Scotland Cancer Care
Glasgow, United Kingdom
St James University Hospital
Leeds, United Kingdom
Barts Cancer Institute - Haemato-Oncology
London, United Kingdom
Start Date
December 10, 2021
Primary Completion Date
November 30, 2023
Completion Date
November 30, 2023
Last Updated
March 17, 2025
NCT06815575
NCT05514132
NCT05508334
NCT04564027
NCT03518606
NCT04434482
Lead Sponsor
Redx Pharma Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions